AIM
ACIU icon

Acrospire Investment Management’s AC Immune ACIU Stock Holding History

Acrospire Investment Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,626
Closed -$73K – 2180
2016
Q4 		$73K Buy
+5,626
New +$77.9K 0.03% 1139

Other funds holding ACIU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Acrospire Investment Management's ACIU Position: Q1 2017 in Review

Acrospire Investment Management sold out of AC Immune (ACIU) in Q1 2017, closing a stake of 5,626 shares — an estimated $73K sold.

Acrospire Investment Management first reported a position in ACIU in Q4 2016 and held it in 1 quarter. The position peaked at $73K in Q4 2016. 18 funds tracked by Wall St. Rank hold ACIU as of Q1 2017.

  • Acrospire Investment Management reported no remaining AC Immune position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 5,626 AC Immune shares in Q1 2017, an estimated $73K.
  • Acrospire Investment Management first reported a position in AC Immune in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's AC Immune position peaked at $73K in Q4 2016.
  • 18 funds tracked by Wall St. Rank held AC Immune as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.